多基因组合检测在静脉血栓栓塞症易栓症检测中的应用
该单中心回顾性分析纳入2019年1月至2023年12月接受血栓形成-止血多基因(THG)组合(含31个诊断级基因)检测的194例静脉血栓栓塞症(VTE)患者,THG组合在63%的患者中检出基因变异,其中半数归类为(可能)致病性变异,36例(19%)携带多基因变异;在185例有常规检测结果的患者中,THG组合检出76例(41%)常规检测无法发现的非兼容性变异,严格一致的遗传学发现见于92例(50%)。作者结论认为THG组合可提供更多易栓症信息,但对患者管理的影响需进一步研究。
要点
- THG多基因组合在63%的VTE患者中检出基因变异,半数归类为(可能)致病性变异。
- 36例(19%)携带多基因变异。
- 185例中76例(41%)检出常规检测无法发现的非兼容性变异,严格一致者92例(50%)。
核心结论
- THG组合可提供更多关于VTE患者潜在易栓症的信息,但其对患者管理的影响需进一步研究。
研究设计与样本
- 单中心回顾性分析,纳入2019年1月至2023年12月接受THG组合(含31个诊断级基因)检测的VTE患者194例,并与常规易栓症检测结果进行比较。
主要发现
- THG组合在194例VTE患者中的63%检出基因变异,其中半数归类为(可能)致病性变异。
- 36例(19%)携带多基因变异。
- 在185例有常规检测结果的患者中,THG组合检出76例(41%)非兼容性变异((可能)致病性变异或意义不明变异),这些变异经常规检测无法发现。
- 严格一致的遗传学发现见于92例(50%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Conventional tests for inherited thrombophilia focus on the 5 most-established inherited thrombophilias; ie deficiencies in antithrombin, protein C, and protein S, and the factor V Leiden and prothrombin G20210A variants. These tests identify thrombophilia in approximately 40% of tested patients with venous thromboembolism (VTE). Next-generation sequencing allows to detect variants in multiple coagulation-related genes, yet its clinical value for VTE remains unknown. OBJECTIVES: This study aimed to report the findings from a multigene coagulation panel for VTE and assess its complementarity to conventional thrombophilia testing in clinical practice. METHODS: We conducted a single-center retrospective analysis of VTE patients tested with the Thrombosis-Hemostasis multigene (THG) panel, comprising 31 diagnostic-grade genes involved in thrombosis and hemostasis, from January 2019 to December 2023. We compared the results of the THG panel with conventional tests and analyzed characteristics associated with positive gene panel results. RESULTS: The THG panel identified genetic variants in 63% of 194 VTE patients. Half of the variants were classified as (likely) pathogenic variants ((L)PVs). Thirty-six (19%) cases carried variants in multiple genes. Among the 185 patients with available conventional test results, the THG panel detected noncompatible variants ([L]PVs or variants of unknown significance) in 76 patients (41%), which would remain undetected by performing conventional tests. Strictly concordant genetic findings were observed in 92 cases (50%). CONCLUSION: The use of the THG panel provides more insights into the underlying thrombophilia of patients with VTE; however, its implications for patient management require further investigation.
引用
- Verstraete A, De Vera MJ, Van Laer C, et al. Multigene panel for thrombophilia testing in venous thromboembolism. J Thromb Haemost. 2025. PMID: 39800257. doi:10.1016/j.jtha.2024.12.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。